Healthcare provider profile · identity verified

Alison Dubasak

Nurse Practitioner · CINCINNATI, OH · NPI 1053887166

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	475	65
Sertraline Hcl	Sertraline Hcl	429	40
Levothyroxine Sodium	Levothyroxine Sodium	368	54
Losartan Potassium	Losartan Potassium	233	48
Rosuvastatin Calcium	Rosuvastatin Calcium	201	24
Amlodipine Besylate	Amlodipine Besylate	184	34
Omeprazole	Omeprazole	175	26
Donepezil Hcl	Donepezil Hcl	157	24
Metformin Hcl	Metformin Hcl	152	19
Eliquis	Apixaban	149	21
Quetiapine Fumarate	Quetiapine Fumarate	143	29
Metoprolol Succinate	Metoprolol Succinate	138	28
Pantoprazole Sodium	Pantoprazole Sodium	134	25
Trazodone Hcl	Trazodone Hcl	133	21
Furosemide	Furosemide	132	31
Potassium Chloride	Potassium Chloride	128	26
Tamsulosin Hcl	Tamsulosin Hcl	128	18
Gabapentin	Gabapentin	127	21
Lisinopril	Lisinopril	125	12
Memantine Hcl	Memantine Hcl	124	22
Escitalopram Oxalate	Escitalopram Oxalate	97	17
Buspirone Hcl	Buspirone Hcl	87	16
Carvedilol	Carvedilol	78	12
Divalproex Sodium	Divalproex Sodium	75	13
Duloxetine Hcl	Duloxetine Hcl	75	11
Mirtazapine	Mirtazapine	75	16
Ezetimibe	Ezetimibe	74	17
Montelukast Sodium	Montelukast Sodium	64	suppressed
Lorazepam	Lorazepam	63	15
Bupropion Xl	Bupropion Hcl	59	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	58	suppressed
Clopidogrel	Clopidogrel Bisulfate	55	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	53	suppressed
Alendronate Sodium	Alendronate Sodium	51	suppressed
Celecoxib	Celecoxib	50	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	50	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	50	suppressed
Allopurinol	Allopurinol	49	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	44	30
Jardiance	Empagliflozin	44	suppressed
Citalopram Hbr	Citalopram Hydrobromide	43	suppressed
Famotidine	Famotidine	41	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Spironolactone	Spironolactone	39	suppressed
Olanzapine	Olanzapine	38	suppressed
Latanoprost	Latanoprost	37	suppressed
Levetiracetam	Levetiracetam	37	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	37	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	36	31
Clonazepam	Clonazepam	34	suppressed
Januvia	Sitagliptin Phosphate	34	suppressed
Amiodarone Hcl	Amiodarone Hcl	33	suppressed
Divalproex Sodium Er	Divalproex Sodium	33	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	31	suppressed
Fluticasone Propionate	Fluticasone Propionate	30	19
Pregabalin	Pregabalin	30	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Azithromycin	Azithromycin	27	22
Albuterol Sulfate Hfa	Albuterol Sulfate	26	15
Tramadol Hcl	Tramadol Hcl	26	11
Lactulose	Lactulose	25	suppressed
Myrbetriq	Mirabegron	24	suppressed
Propranolol Hcl	Propranolol Hcl	24	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Entresto	Sacubitril/Valsartan	22	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	22	suppressed
Sucralfate	Sucralfate	22	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Glipizide	Glipizide	20	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Rivastigmine	Rivastigmine Tartrate	20	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	20	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	19	suppressed
Baclofen	Baclofen	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Prednisone	Prednisone	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Gemfibrozil	Gemfibrozil	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Primidone	Primidone	17	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Solifenacin Succinate	Solifenacin Succinate	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Methylprednisolone	Methylprednisolone	14	13
Risperidone	Risperidone	14	suppressed
Torsemide	Torsemide	14	suppressed
Alphagan P	Brimonidine Tartrate	13	suppressed
Colestipol Hcl	Colestipol Hcl	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Estradiol	Estradiol	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Ranolazine Er	Ranolazine	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Ursodiol	Ursodiol	13	suppressed
Atenolol	Atenolol	12	suppressed
Dofetilide	Dofetilide	12	suppressed
Lithium Carbonate	Lithium Carbonate	12	suppressed
Rivastigmine	Rivastigmine	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Amantadine	Amantadine Hcl	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Simvastatin	Simvastatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error